Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
Identifieur interne : 001503 ( Istex/Corpus ); précédent : 001502; suivant : 001504Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
Auteurs : John G. NuttSource :
- Movement Disorders [ 0885-3185 ] ; 2007-01.
English descriptors
- KwdEn :
Abstract
Continuous dopaminergic stimulation (CDS) is a treatment strategy hypothesized to avoid or reduce the motor complications of long‐term levodopa therapy, motor fluctuations, and dyskinesia, by preventing or reversing sensitization induced by pulsatile dopaminergic stimulation. The CDS hypothesis is itself based on several hypotheses. First, tonic dopaminergic stimulation is physiological. Second, sensitization is undesirable and should be reversed. Third, reduction of off time and dyskinesia can be induced simultaneously. Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21060
Links to Exploration step
ISTEX:9C5665D2D52950709DB3E36453FB462C55E21011Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name><affiliation><mods:affiliation>Northwest PADRECC, Portland VAMC, and Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9C5665D2D52950709DB3E36453FB462C55E21011</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21060</idno><idno type="url">https://api.istex.fr/document/9C5665D2D52950709DB3E36453FB462C55E21011/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001503</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name><affiliation><mods:affiliation>Northwest PADRECC, Portland VAMC, and Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01">2007-01</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="9">9</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9C5665D2D52950709DB3E36453FB462C55E21011</idno><idno type="DOI">10.1002/mds.21060</idno><idno type="ArticleID">MDS21060</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>continuous dopaminergic stimulation</term><term>levodopa</term><term>randomized clinical trials</term><term>sensitization</term><term>tolerance</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Continuous dopaminergic stimulation (CDS) is a treatment strategy hypothesized to avoid or reduce the motor complications of long‐term levodopa therapy, motor fluctuations, and dyskinesia, by preventing or reversing sensitization induced by pulsatile dopaminergic stimulation. The CDS hypothesis is itself based on several hypotheses. First, tonic dopaminergic stimulation is physiological. Second, sensitization is undesirable and should be reversed. Third, reduction of off time and dyskinesia can be induced simultaneously. Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized. © 2006 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>John G. Nutt MD</name><affiliations><json:string>Northwest PADRECC, Portland VAMC, and Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>continuous dopaminergic stimulation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>sensitization</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>tolerance</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>randomized clinical trials</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Continuous dopaminergic stimulation (CDS) is a treatment strategy hypothesized to avoid or reduce the motor complications of long‐term levodopa therapy, motor fluctuations, and dyskinesia, by preventing or reversing sensitization induced by pulsatile dopaminergic stimulation. The CDS hypothesis is itself based on several hypotheses. First, tonic dopaminergic stimulation is physiological. Second, sensitization is undesirable and should be reversed. Third, reduction of off time and dyskinesia can be induced simultaneously. Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized. © 2006 Movement Disorder Society</abstract><qualityIndicators><score>6.224</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>764</abstractCharCount><pdfWordCount>6091</pdfWordCount><pdfCharCount>41435</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>102</abstractWordCount></qualityIndicators><title>Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title><genre><json:string>Serial article</json:string></genre><host><volume>22</volume><pages><total>9</total><last>9</last><first>1</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Review</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21060</json:string></doi><id>9C5665D2D52950709DB3E36453FB462C55E21011</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/9C5665D2D52950709DB3E36453FB462C55E21011/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/9C5665D2D52950709DB3E36453FB462C55E21011/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/9C5665D2D52950709DB3E36453FB462C55E21011/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2007</date></publicationStmt><notesStmt><note>Veterans' Administration PADREC</note><note>National Institutes of Health - No. NIH‐NINDS R01‐NS21062;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title><author><persName><forename type="first">John G.</forename><surname>Nutt</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Oregon Health & Science University, Portland VAMC Northwest PADRECC, Oregon Health & Science University, Parkinson Center of Oregon, 3181 SW Sam Jackson Park Road, OP32, Portland, OR 97239‐3098</p></note><affiliation>Northwest PADRECC, Portland VAMC, and Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01"></date><biblScope unit="vol">22</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="9">9</biblScope></imprint></monogr><idno type="istex">9C5665D2D52950709DB3E36453FB462C55E21011</idno><idno type="DOI">10.1002/mds.21060</idno><idno type="ArticleID">MDS21060</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Continuous dopaminergic stimulation (CDS) is a treatment strategy hypothesized to avoid or reduce the motor complications of long‐term levodopa therapy, motor fluctuations, and dyskinesia, by preventing or reversing sensitization induced by pulsatile dopaminergic stimulation. The CDS hypothesis is itself based on several hypotheses. First, tonic dopaminergic stimulation is physiological. Second, sensitization is undesirable and should be reversed. Third, reduction of off time and dyskinesia can be induced simultaneously. Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized. © 2006 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>levodopa</term></item><item><term>continuous dopaminergic stimulation</term></item><item><term>sensitization</term></item><item><term>tolerance</term></item><item><term>randomized clinical trials</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2005-12-02">Received</change><change when="2006-04-18">Registration</change><change when="2007-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/9C5665D2D52950709DB3E36453FB462C55E21011/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v22:1</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2007-01">January 2007</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="10" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21060</doi><idGroup><id type="unit" value="MDS21060"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Review</title></titleGroup><copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2005-12-02"></event><event type="manuscriptRevised" date="2006-02-16"></event><event type="manuscriptAccepted" date="2006-04-18"></event><event type="firstOnline" date="2006-09-06"></event><event type="publishedOnlineFinalForm" date="2007-01-22"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2006-09-06"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1</numbering><numbering type="pageLast">9</numbering></numberingGroup><correspondenceTo>Oregon Health & Science University, Portland VAMC Northwest PADRECC, Oregon Health & Science University, Parkinson Center of Oregon, 3181 SW Sam Jackson Park Road, OP32, Portland, OR 97239‐3098</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21060.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="96"></count><count type="wordTotal" number="6792"></count></countGroup><titleGroup><title type="main" xml:lang="en">Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title><title type="short" xml:lang="en">Continuous Dopaminergic Stimulation</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>John G.</givenNames><familyName>Nutt</familyName><degrees>MD</degrees></personName><contactDetails><email>nuttj@ohsu.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Northwest PADRECC, Portland VAMC, and Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">levodopa</keyword><keyword xml:id="kwd2">continuous dopaminergic stimulation</keyword><keyword xml:id="kwd3">sensitization</keyword><keyword xml:id="kwd4">tolerance</keyword><keyword xml:id="kwd5">randomized clinical trials</keyword></keywordGroup><fundingInfo><fundingAgency>Veterans' Administration PADREC</fundingAgency></fundingInfo><fundingInfo><fundingAgency>National Institutes of Health</fundingAgency><fundingNumber>NIH‐NINDS R01‐NS21062</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Continuous dopaminergic stimulation (CDS) is a treatment strategy hypothesized to avoid or reduce the motor complications of long‐term levodopa therapy, motor fluctuations, and dyskinesia, by preventing or reversing sensitization induced by pulsatile dopaminergic stimulation. The CDS hypothesis is itself based on several hypotheses. First, tonic dopaminergic stimulation is physiological. Second, sensitization is undesirable and should be reversed. Third, reduction of <i>off</i> time and dyskinesia can be induced simultaneously. Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized. © 2006 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Continuous Dopaminergic Stimulation</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title></titleInfo><name type="personal"><namePart type="given">John G.</namePart><namePart type="family">Nutt</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Northwest PADRECC, Portland VAMC, and Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon, USA</affiliation><description>Correspondence: Oregon Health & Science University, Portland VAMC Northwest PADRECC, Oregon Health & Science University, Parkinson Center of Oregon, 3181 SW Sam Jackson Park Road, OP32, Portland, OR 97239‐3098</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">reviewArticle</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-01</dateIssued><dateCaptured encoding="w3cdtf">2005-12-02</dateCaptured><dateValid encoding="w3cdtf">2006-04-18</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">96</extent><extent unit="words">6792</extent></physicalDescription><abstract lang="en">Continuous dopaminergic stimulation (CDS) is a treatment strategy hypothesized to avoid or reduce the motor complications of long‐term levodopa therapy, motor fluctuations, and dyskinesia, by preventing or reversing sensitization induced by pulsatile dopaminergic stimulation. The CDS hypothesis is itself based on several hypotheses. First, tonic dopaminergic stimulation is physiological. Second, sensitization is undesirable and should be reversed. Third, reduction of off time and dyskinesia can be induced simultaneously. Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized. © 2006 Movement Disorder Society</abstract><note type="funding">Veterans' Administration PADREC</note><note type="funding">National Institutes of Health - No. NIH‐NINDS R01‐NS21062; </note><subject lang="en"><genre>Keywords</genre><topic>levodopa</topic><topic>continuous dopaminergic stimulation</topic><topic>sensitization</topic><topic>tolerance</topic><topic>randomized clinical trials</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>1</start><end>9</end><total>9</total></extent></part></relatedItem><identifier type="istex">9C5665D2D52950709DB3E36453FB462C55E21011</identifier><identifier type="DOI">10.1002/mds.21060</identifier><identifier type="ArticleID">MDS21060</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001503 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001503 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:9C5665D2D52950709DB3E36453FB462C55E21011
|texte= Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
}}
| This area was generated with Dilib version V0.6.23. |  |